Fig. 3.
Fas-mediated killing of EBV-transformed B-cell lines derived from 7 ALPS patients and 16 normal controls. The percentage of cell loss was calculated from cultures of EBV-transformed B-cell lines exposed to the anti-Fas MoAb CH11. Patient no. 14 lacked a Fas mutation. Mean and standard deviation are shown for controls.